Heart Force Medical Inc.

Presenter: Geoffrey Houlton, President and CEO

Company Profile

Heart Force Medical Inc. (HFM) has invented and has patents pending for the digital ballistocardiograph (dBG), a non-invasive medical device
that assesses cardiac function. The dBG is a recording of the motion of the lower sternum resulting from the movement of the heart during each cardiac cycle (heartbeat). The movement (acceleration or force) is sensed by a tri-axial accelerometer aligned to the three principal axes, processed digitally, and displayed with the acceleration amplitudes as the vertical axis and time as the horizontal axis. Measurement of acceleration is expressed in milli-gravity (mG) units and time is recorded in milliseconds (ms). A single electrocardiograph (ECG) is sensed and recorded simultaneously with the dBG. Preliminary evaluation has determined that a 1030-second recording of the dBG waveform is sufficient for a detailed analysis of cardiac performance. All data are displayed on a computer screen using HFM proprietary software. The dBG 300TM is certified by Health Canada, the US FDA and has secured the CE Marking for European distribution.HFM is also ISO 13485 certified.The Company is currently refining its product offering to address the significant market opportunity presented by Cardiac Resynchronization Therapy (CRT) an invasive treatment for NYHA class III/IV Heart Failure patients. This market sector is dominated by three multi-national medical device companies who share 97% of the available $5 billion market. HFM has identified a unique solution to the known problem of patient selection and objective assessment of effectiveness of treatment for this extremely expensive therapy. HFM announced the completion of a private financing in January 2010.HFM is currently a private company.

Company Strategy

Establish an early independant revenue stream then partner with a substantial medical device company with significant international presence to enable rapid and effective penetration of the cardiac resynchronization therapy (CRT) market which has grown at double digit percentages since the products were launched in 2001.

Intellectual Property

Sevefral families of patents focused on hardware and software engineering in ballistocardiography and seismocardiography. Patents pending in USPTO and PCT countries in the world's major markets.

Programs

Focused on the assessment and monitoring of patients with cardiovascular disease, specifically heart failure and ischemia, for use by EP-cardiologists, general cardiologists and finally general practitioners

Investors

Three Toronto-based institutions
Canadian private high-net worth individuals

Management Team

CEO - Dr Geoff Houlton
CFO - Issa Nakleh
Dir Engineering and Technology - Sandy Burns
Dir Product Development - Adrian Somers

Presenter Bio

DR. GEOFF HOULTON - President and Chief Executive Officer
Dr. Houlton qualified in Medicine in Scotland in 1977. In 1983, after residency training in anesthesiology, he joined the UK pharmaceutical industry.
In 1987 he became Vice-President of Medical Affairs for Glaxo Canada Inc. and managed all aspects of their local pharmaceutical product development programs. He has extensive experience in product development in both the European and North American markets.
In 1989, the challenges of product and business development lead him to join MDS Health Ventures Ltd.
In 1997 he was a Founder of BioCatalyst Yorkton Inc, a venture management company with Yorkton Securities.
Dr Houlton has served as a Senior Health Sciences Analyst for a number of Canadian investment banks.
In December 2008 Dr Houlton was invited to become President and Chief Executive Officer of Heart Force Medical Inc.

Contact

Heart Force Medical Inc.
#305 - 1818 Cornwall Avenue
Vancouver
BC, Canada
V6J 1C7

ph: 604 566 8202
fx: 604 566 8201

www.heartforcemedical.com
geoff.houlton@heartforcemedical.com

April 6-8, 2010